Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

Ysebaert, L; Gross, E; Kühlein, E; Blanc, A; Corre, J; Fournié, J J; Laurent, G; Quillet-Mary, A

Ysebaert, L; Gross, E; Kühlein, E; Blanc, A; Corre, J; Fournié, J J; Laurent, G; Quillet-Mary, A.

Affiliation

Ysebaert L; Inserm U563, Université Toulouse III Paul-Sabatier, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France. ysebaert.l@chu-toulouse.fr

Leukemia ; 24(7): 1310-6, 2010 Jul.

Article in En | MEDLINE | ID: mdl-20463751

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell/immunology; Adult; Aged; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide/administration & dosage; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunomodulation; Killer Cells, Natural/immunology; Leukemia, Lymphocytic, Chronic, B-Cell/pathology; Male; Middle Aged; Neoplasm Recurrence, Local/diagnosis; Neoplasm Recurrence, Local/drug therapy; Neoplasm Recurrence, Local/pathology; Neoplasm, Residual/diagnosis; Neoplasm, Residual/drug therapy; Neoplasm, Residual/pathology; Prognosis; Rituximab; Survival Rate; Vidarabine/administration & dosage; Vidarabine/analogs & derivatives

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Immunotherapy Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2010 Type: Article

Fulltext

XML

PubMed Links

Search on Google